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treatment (ART) has made HIVAC less common and improved 
outcomes, HIV infection remains a major risk factor for cardiac 
dysfunction.(3) There is currently no universally accepted termi-
nology for HIVAC. HIVAC is a collective term used to describe 
a number of cardiomyopathic findings that may not have a 
clear cause. It is helpful to broadly categorise HIVAC into 3 
groups: i) Myocarditis; ii) Asymptomatic diastolic or systolic 
ventricular dysfunction; and iii) Symptomatic dilated cardio-
myopathy with reduced systolic function.(9) Treatment is chal-
lenging due to the poorly understood pathophysiology and 
the lack of clinical trials to provide evidence for the tailored 
management of these patients. It is unclear if current guideline 
directed medical therapy is the best option to optimise long 
term outcomes. Furthermore, it remains unknown which treat-
ments supplementing ART are required to adequately prevent 
and treat HIVAC.(6) 
This narrative review will highlight similarities between sympto-
matic and asymptomatic HIV associated myocardial pathology 
as observed with cardiovascular magnetic resonance (CMR). 
Our understanding and the significance of myocardial pathol-
ogy in asymptomatic PLWH will be explored as early disease 
on a continuum towards more advanced disease. Furthermore, 
INTRODUCTION
HIV associated cardiomyopathy (HIVAC) has a poorly 
understood pathology
Human immunodeficiency virus (HIV) infection and cardio-
vascular disease (CVD) are intimately related, and a leading 
cause of death and disability worldwide.(1,2) Previous literature 
emphasises the variety of CVD encountered in people living 
with HIV (PLWH).(3) However, the coronary disease burden 
seen in high-income countries contrasts with what is experi-
enced in low- and middle-income countries(3,4) where the vast 
majority of PLWH reside.(5) In these resource-limited countries, 
myocardial disease remains prevalent.(4,6,7) Cardiomyopathy is a 
feared HIV-complication with a poor prognosis once systolic 
dysfunction is present.(8) Although the rollout of anti-retroviral 
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the need for prospective research in persons naive to ART will 
be discussed as it may provide clues to a better understanding 
of this elusive disease process. 
THe TOOl Of CHOICe – CMR AND VIRTUAl 
HIsTOlOgy
To explore underlying pathological processes of disease, his-
tology-based research has long been the gold standard. 
Unfortunately, this form of investigation is limited by the 
invasive nature of antemortem tissue biopsies or necropsies.
Echocardiography has been the workhorse modality for evalu-
ating cardiac structure and function in the clinical context. 
Unfortunately, this modality requires significant numbers to 
discern differences between groups in the study context due 
to modest inter- and intra-observer variability.(10) This becomes 
relevant when noting that echocardiography studies assessing 
myocardial disease mechanisms in PLWH remain relatively 
small. The use of strain-imaging improves echocardiography’s 
ability to detect functional abnormalities of the myocardium. 
This modality has been used to study PLWH and has demon-
strated subtle myocardial abnormalities that are present well 
before symptoms, biochemical evidence, or conventional echo-
cardiographic findings of myocardial dysfunction.(11) Unfortu-
nately, strain-abnormalities remain non-specific as they only 
provide functional information on myocardial contraction 
mechanics and deformation.(12,13) Strain-imaging cannot char-
acterise tissues and is therefore unable to obtain direct evi-
dence of pathological processes that underlie myocardial 
dysfunction. 
CMR allows for comprehensive, serial evaluation of cardiac 
structure and function. Evaluation of pathology through a virtual 
histology approach is a unique feature of CMR. This allows for 
non-invasive examination of pathological processes and how 
they interact with the observed cardiac structure and function 
in vivo. It is an excellent tool to non-invasively obtain informa-
tion on myocardial tissue at varying clinical stages of disease. 
These include the presence of inflammation, oedema, necrosis, 
fibrosis, infarction, infiltration and thrombosis.(14,15) Non-invasive 
measurement of tissue characteristics have led to the develop-
ment of CMR-biomarkers. T1, T2 and T2* (T2 star) are mag-
netic resonance imaging (MRI) measurements that represent 
different tissue relaxation parameters following excitation by 
a radiofrequency pulse.(16) Different tissues have unique T1, 
T2 and T2* properties that can be used to demonstrate 
specif ic tissue characteristics or pathological processes in a 
magnetic resonance image. These imaging biomarkers may be 
used to support the diagnosis, to prognosticate disease, and 
for surveillance during treatment.(17) Examples include T2* 
measurement to guide iron chelation therapy in thalassemia 
and haemochromatosis(18) and T1/extracellular volume (ECV) 
measurement to monitor amyloidosis treatment.(17) Limited 
studies evaluating the myocardial tissue characteristics of PLWH 
have been published.(19-21) A number of observations from the 
CMR scans of PLWH offer insight into the direction that may 
be taken to shed light on the underlying myocardial pathology. 
CAse RepORTs
Two case reports are presented demonstrating the evolution 
of symptomatic HIVAC as studied by CMR. These cases will be 
utilised as a point of departure and substrate for discussion in 
this article. 
Case 1
A 27-year-old female with no prior cardiovascular disease or 
symptoms, presented with an embolic stoke. She was known 
to be HIV-infected, but naive to ART with a CD4 count of 
61 cells/microlitre. She denied smoking, excessive alcohol 
consumption or injection drug use. No nutritional deficiencies 
were suspected. She presented 2 years before the worldwide 
coronavirus disease 2019 (COVID-19) outbreak. Abnormalities 
seen on echocardiography prompted a CMR study with key 
findings shown in Figure 1, left panel. Left ventricular (LV) 
systolic function was impaired with an ejection fraction of 48% 
(see online supplement video clip). The LV was non-dilated, 
suggesting an acute/subacute process. Indexed LV end dias- 
tolic volume measured 64ml/m2. Furthermore, the LV walls 
appeared thickened. The LV mass index measured high normal 
at 72g/m2. Myocardial oedema was demonstrated by an 
increased signal on short tau inversion recovery (STIR) images. 
These T2-weighted images are designed to demonstrate high 
signal in tissues with an increased water content (oedema).(16)
These findings were consistent with a frequently encountered 
myocardial phenotype seen in PLWH, namely poorly functional 
ventricles with a high LV mass index. This phenomenon of 
heavier ventricles has been explored using echocardiography 
in asymptomatic PLWH and is independently associated with 
HIV infection.(22)
Oedema as part of an inflammatory process in the myocar-
dium was the most likely explanation for the CMR findings. 
An endomyocardial biopsy (EMB) confirmed myocarditis, 
with the viral panel screening negative for parvovirus B19, 
respiratory viruses and enteroviruses. Serology for Hepatitis B 
virus was negative. Autoimmune workup, including anti-nuclear 
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fIgURe 1: Comparative findings in an HIV positive female with HIV-associated cardiomyopathy before (1, left panel) and 9 
months after initiation of antiretroviral treatment (2, right panel). 
(A) basal short axis, end diastolic frames of cine imaging. Left ventricular ejection fraction at baseline measured 48% and improved to 59% on 
treatment. Indexed left ventricular end diastolic volume at baseline and follow-up were 64ml/m2 and 72ml/m2 respectively. The left ventricular 
mass index improved from a baseline value of 72g/m2 to 56g/m2. 
(B) basal short axis, phase sensitive inversion recovery images showing midmyocardial late gadolinium enhancement (LGe) of the septum at 
baseline and follow-up (white arrows). 
(C) 4-Chamber, short tau inversion recovery (sTIr) image showing myocardial: skeletal signal ratio (white circles) of 2.6, indicative of ventricular 
oedema at baseline (C1). sTIr imaging at follow up (C2) demonstrated myocardial: skeletal signal ratio (white circles) of 2.6, suggesting ongoing 


























antibodies, was negative. The etiology therefore remained 
largely unexplained.
Follow-up CMR-evaluation allowed the prospective study of 
disease evolution after the initiation on ART. At the time of 
follow up, the CD4 count had improved to 172 cells/microlitre, 
despite the patient not achieving viral suppression (viral load = 
252 405 copies/ml). Within a relatively short period of time (9 
months on ART), the LV ejection fraction improved to 59% 
and the left ventricular mass index decreased to 56g/m2. The 
indexed LV end diastolic volume remained fairly similar at 
72ml/m2. The longitudinal systolic function (not shown) did not 
fully recover and evidence of persistent myocardial inflamma-
tion was present (Figure 1, C2). 
The observation of ongoing myocardial inflammation despite 
treatment supports contemporary literature on myocardial 
pathology in PLWH and will be discussed later in the article. 
The persistence of late gadolinium enhancement (LGE) in the 
septum supports the presence of myocardial fibrosis and is 
consistent with the pattern of LGE seen in dilated cardio-
myopathies, irrespective of aetiology.(18) 
LGE is currently the reference standard for non-invasive 
demonstration of myocardial scar and focal fibrosis in both 
ischaemic and non-ischaemic pathologies.(17) LGE is most 
notably associated with myocardial necrosis and fibrosis, but 
may be present with ventricular oedema if the degree of inter-
stitial expansion is large enough.(23) Gadolinium-based contrast 
agents do not cross intact cell membranes and therefore dis-
tribute exclusively in the extracellular space. After intravenous 
administration, gadolinium is trapped in expanded intersti- 
tium, lowering the T1 time of these abnormal tissues. The wash 
out time of gadolinium in tissues with an expanded intersti- 
tium is longer than normal tissue. This increases the signal 
during delayed enhancement imaging and allows for improved 
contrast between normal and abnormal tissues.(24) Interstitial 
oedema, replacement fibrosis and myocardial necrosis are all 
causes of interstitial expansion.(18) The degree of interstitial 
expansion from oedema is typically less than with replace- 
ment f ibrosis and necrosis. This gives a picture of less 
intense gadolinium signal (“bland gadolinium”) as opposed to 
the brighter signal typically seen in infarction and replace-
ment fibrosis. Interstitial expansion from oedema may how-
ever be marked when an associated cellular infiltrate is pre- 
sent.(25) As an extracellular contrast agent, the gadolinium will 
only occupy the non-cellular component of the expanded 
extracellular space. As such, the cellular infiltrate acts to 
“dilute” the gadolinium in this total expanded space leading to 
a less intense gadolinium signal. Therefore, “bland gadolin-
ium” may be encountered despite marked interstitial expan-
sion where a large fraction of this is related to cellular infiltrates. 
The intensity of LGE may decrease between CMR studies if 
the degree of oedema has improved sufficiently without 
accompanying fibrosis.(23)
LGE imaging is an excellent modality to diagnose focal myo-
cardial abnormality as seen in replacement fibrosis. The inter-
pretation of LGE findings may, however, be challenging when 
global myocardial pathology is present. This includes diffuse 
myocardial fibrosis as is frequently encountered in common 
pathologies including hypertensive heart disease and aortic 
stenosis. Furthermore, global myocardial oedema may be pre-
sent in pan-myocarditis associated with systemic diseases such 
as systemic lupus erythematosus, rheumatoid arthritis and likely 
HIV.(26) This is due to the fact that LGE assessment is usually a 
qualitative evaluation and involves comparison with an area of 
normal myocardium by the observer. If global, homogenous 
LGE of the myocardium is present, comparison with a normal 
myocardial reference area is not possible. It is therefore pos-
sible that LGE may be missed in these scenarios. Tools used to 
quantify LGE have been developed. Like visual LGE assess-
ment, LGE quantification is dependent on an area of normal 
myocardium that serves as a reference against which abnorma-
lity is assessed.(17) When global LGE is present, the same 
problem is faced as with visual assessment - no normal myo-
cardial reference is possible and measurement accuracy is 
decreased. Furthermore, the use of gadolinium-based contrast 
agents may be contra-indicated in patients with severe renal 
disease as these agents have been associated with rare cases 
of nephrogenic systemic f ibrosis.(23) The above challenges 
can be overcome by employing CMR’s myocardial mapping 
techniques.(17) 
Myocardial mapping sequences are gaining popularity to study 
focal and global myocardial processes and have distinct 
advantages over LGE imaging. These robust imaging sequences 
allow for quantitative evaluation of the myocardium without 
the need for a normal reference region. Another advantage of 
mapping sequences is that they do not generally require 
gadolinium administration and are safe to use in patients at 
higher risk for nephrogenic systemic fibrosis. These sequences 
allow for serial evaluation and comparison of quantitative 
imaging biomarkers T1, T2, T2* and ECV. 
Mapping sequences were employed to prospectively study a 
patient with symptomatic HIVAC demonstrating the utility of 
these sequences to compare imaging biomarkers over time.
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Case 2
A 38-year-old male presented with a one-week history of 
symptoms in keeping with left sided cardiac failure following a 
flu-like illness. He did not report any prior illness, excessive 
alcohol consumption or injection drug use. He appeared 
chronically unwell with generalised body wasting and a body 
mass index of 19kg/m2. No evidence of specific nutritional 
deficiencies were present. He was diagnosed with HIV at pre-
sentation and had a CD4 count of 208 cells/microlitre. An 
echocardiogram demonstrated marked structural and func-
tional abnormalities. A CMR study was performed at the time 
of presentation to assist workup (Figure 2). The LV was dilated 
and had a severely reduced ejection fraction of 26% (see online 
supplement video clip). The ventricular walls were markedly 
thickened with a maximum septal measurement of 17mm. 
Indexed LV end diastolic volume and mass measured 153ml/m2 
and 180g/m2 respectively – both notably raised. Overt myo-
cardial oedema was present as evidenced by high T1 and T2 
mapping values, as well as a global average STIR myocardial: 
skeletal muscle ratio of 2.5 (not shown). An endomyocardial 
biopsy confirmed myocarditis with no causative organism 
identified on the viral panel. The panel included screening for 
parvovirus B19, respiratory- viruses, herpes-, and enteroviruses. 
Serology for Hepatitis B virus was negative. Autoimmune 
workup, including anti-cardiac antibodies, was negative.
A follow up CMR was performed 4 months after initiation on 
ART and anti-failure treatment (Figure 2, right). The patient had 
an undetectable viral load at this time. The LV ejection fraction 
had improved from 26% - 45% on treatment. The indexed LV 
end diastolic volume and LV mass index improved to 119ml/m2 
and 158g/m2, respectively. Septal thickness remained unchanged 
at 17mm. Global average STIR myocardial: skeletal muscle ratio 
decreased to 1.94, which is borderline for myocardial oedema.
In the absence of other aetiologies, these two HIV-positive 
patients demonstrate clear symptomatic myocardial patho- 
logy. The myocardial involvement of case 2 is significantly more 
advanced than case one, but shared features of chronic 
myocarditis are evident: poorly contractile, oedematous ven-
tricles that improve, but do not normalise on ART. Persistent 
myocardial inflammation was observed in both cases, irrespec-
tive of whether viral suppression was achieved or not. The 
aetiology of their cardiomyopathies remains elusive and forces 
us to confront our incomplete understanding of myocardial 
pathology in HIV. These cases give us the opportunity to 
demonstrate the effects of ART on symptomatic myocardial 
disease over time using CMR. This strategy will prove invaluable 
in future research to disentangle a complex, multifactorial 
disease process. 
THe pATHOlOgy Of HIVAC – key kNOwleDge 
gAps ReMAIN
The pathophysiology of HIVAC is complex and has proven to 
be difficult to research. Various hypotheses have been pro-
posed and involve chronic inflammation secondary to immune 
activation, post-infective cardiac autoimmunity, primary or 
secondary HIV myocarditis, immunodeficiency, opportunistic 
infections, complications of ART, nutritional deficiencies, tra-
ditional risk factors, as well as alcohol consumption and 
smoking.(6,9,14,19,27-33) It is not known whether a genetic pre-
disposition to HIVAC exists and limited research has been 
performed in this field.(34)
In practice, the cause is most probably multifactorial and likely 
to represent a complex interplay of one or more of these 
processes. Chronic myocardial inflammation appears to be a 
key finding and cumulative myocardial damage from inflam-
mation has been proposed.(19) Inflammation may be a com- 
mon pathophysiological endpoint of various processes that 
work synergistically to create the perfect storm for myocar-
dial damage (Figure 3). The relative contribution of these 
factors may vary depending on the setting, as different causes 
have been noted between high-income and low-income 
countries, as well as virologically supressed and unsuppressed 
individuals.(6) The influence of ART on the reversibility of myo-
cardial abnormalities that are already present remain largely 
unstudied. Current evidence suggests that even modern ART is 
not the sole answer to prevent and treat HIVAC.(19) Many 
questions remain unanswered, including to what degree viral 
suppression protects the myocardium from disease progres-
sion and during what stage of HIV infection myocardial 
pathology starts to manifest. Further research is clearly required. 
With the advent of more accessible ART worldwide, the focus 
of research on CVD in PLWH has begun to shift. An area of 
interest is the study of asymptomatic PLWH.
THe blACk bOx
do all pLWH develop some degree of asymptomatic 
myocardial involvement yet only some progress to 
symptomatic cardiomyopathy?
A number of authors have investigated asymptomatic myo-
cardial pathology in PLWH using various modalities. Findings 
have shown a previously underappreciated burden of sub-
clinical cardiomyopathy. Pre-ART era research from a low-
income, African country observed dilated cardiomyopathy using 
echocardiography in 17.7% of asymptomatic PLWH.(35) Simi-














fIgURe 2: Comparative findings in a male with HIV-associated cardiomyopathy before (1, left panel) and 4 months on 
antiretroviral treatment (2, right panel). 
(A) midventricular short axis, end diastolic frames of cine imaging. resolution of pericardial effusion (white arrow, A1) on treatment. Left 
ventricular ejection fraction at baseline was 26% and improved to 45% on treatment. Indexed left ventricular end diastolic volume at baseline and 
follow-up were 153ml/m2 and 119ml/m2 respectively. The left ventricular mass index improved from a baseline value of 180g/m2 to 158g/m2. 
(B) midventricular short axis, phase sensitive inversion recovery images showing late gadolinium enhancement (LGe) in the inferior septum that 
decreased at follow-up (white arrows). 
(C) midventricular short axis, T1 mapping images showing high septal T1 values before treatment (C1) with improvement on treatment (C2). 
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cardiograms on 69 newly diagnosed HIV positive patients not 
suspected of having cardiovascular disease. Unexpectedly, 
14.5% had myopathic ventricles at baseline. During an 11- 
month follow-up period, 18.6% of the participants with normal 
hearts at baseline subsequently developed echocardiographic 
evidence of cardiomyopathy in the absence of ART. The pre-
valence of HIVAC in this cohort was as high as 30.4%.(36) Had 
current CMR technology been employed to study these 
individuals, it is not unreasonable to speculate that the pre-
valence of myocardial abnormalities may have been even 
higher. Furthermore, this study demonstrated the progression 
of HIVAC in a large proportion of patients with the only 
demonstrable risk being a CD4 count of less than 100 cells/
microlitre. No meaningful association with alcohol abuse, 
smoking, diabetes, an AIDS diagnosis, or diastolic hypertension 
were demonstrable. A trend of higher rates of cardiomyo- 
pathy in patients older than 40 years was present but did not 
prove statistically significant. 
A Brazilian autopsy/histopathology-based study investigated 94 
patients with AIDS in the absence of ART. Varying degrees of 
cardiac dilatation was described in 74% of necropsies. The 
macroscopically remodelled hearts were not related to any 
known cardiovascular disease. When investigating the hearts 
microscopically, a variety of pathological cardiac alterations 
were present in almost all cases. These findings included myo-
cardial alterations in the form of interstitial fibrosis in 45.5% of 
cases and interstitial mononuclear infiltrate in all cases. On 
ultrastructural level, interstitial oedema was observed in all 
cases, with cardiomyocyte apoptosis present in 44% of the 
cohort.(37) Cardiac steatosis was a rare finding, with only mild 
steatosis reported in 4.5% of cases. 
These findings emphasise a clear disconnect in the literature: 
PLWH have almost universal underlying myocardial pathology, 
yet only some individuals develop symptomatic disease. This 
observation leaves the impression that myocardial involvement 
is on a continuum of disease, ranging from trivial inflammation 
in otherwise normal hearts to a poorly prognostic dilated car-
diomyopathy phenotype. What happens in a real world setting 
between these two extremes remains unknown. Patients with 
subtle, largely undiagnosed myocardial abnormalities receive 
ART and enter the “Black Box” (Figure 3). Years later we are 
faced with a subset of patients who developed symptomatic 
cardiomyopathy or are found to have asymptomatic cardio-
myopathy with no clear idea as to what happened in the 
interim. Identifying patients at greatest risk for progression, 
predictors of disease attenuation and the most effective sur-
veillance and treatment modalities remain unclear.
To develop strategies to answer the above questions, 
researchers need to establish a timeline for HIVAC which 
describes the disease phenotype at different time points in its 
progression. 
Holloway, et al. utilised CMR and spectroscopy to study asymp-
tomatic PLWH already on ART in the United Kingdom.(21) 
The authors demonstrated altered myocardial functioning, 
myocardial steatosis and fibrosis in their participants. The high 
rate of cardiac steatosis is thought to be the result of ART-
related metabolic derangement. The low prevalence of steato-
sis in autopsy-studies in pre-ART era AIDS patients(37) sup- 
ports the theory of ART induced myocardial toxicity. Investi-
gating persons on ART may further confound the interpreta-
tion of f indings, as this group already has various potential 
mechanisms of myocardial damage. In order to disentangle 
these various processes, the need for work on ART naive 
individuals has been emphasised.
Appraising CMR-publications that studied asymptomatic, ART-
naive individuals, myocardial abnormalities appear to be pre-
sent before the initiation of ART. The work of Holloway, et al. 
was expanded upon by Ntusi, et al.(19) The enlarged cohort 
included 13 PLWH naive to ART and sought to compare 
myocardial inflammation and oedema in various patient groups, 
including HIV uninfected controls. Compared to treated 
individuals, the ART naive subgroup demonstrated decreased 
left ventricular ejection fraction. Treated and untreated indivi-
duals had equally high rates of myocardial LGE (82% vs. 85%). 
LGE was most frequently visualised in the septum, posterior, 
and lateral segments of the base and mid-ventricle. Compared 
to HIV uninfected controls, the ventricular mass and oedema 
markers were significantly increased in both treated and 
untreated PLWH. 
Findings from the high- to middle-income country of Peru 
were briefly discussed in a letter to the editor by Menacho, 
et al.(20) The authors report similar findings of subtle reduced 
systolic functioning and high rates of LGE in untreated and 
treated PLWH. The pattern of LGE was similar to what was 
seen by Ntusi, et al.: septal and posterior segment involve-
ment. Notable findings in this group are a global increase in 
native T1, T2 and ECV found in PLWH. Unfortunately, no data 
on LV mass was presented for comparison. 
The findings of Holloway, et al., Ntusi, et al. and Menacho, et al. 
all mirror the observations in symptomatic cardiomyopathy 
presented in cases 1 and 2 (Figures 1 and 2): Thickened, inflamed 














similarity of symptomatic and asymptomatic cases are striking, 
the degree to which subclinical myocardial abnormality is a 
harbinger of more advanced pathology, and to what extent 
ART will improve or halt evolution of abnormalities remains 
unknown.(28)
A recent biochemical study has provided evidence to suggest 
that an inflammatory cardiomyopathy is present at the time of 
HIV-seroconversion. It was demonstrated that subclinical car-
diac dysfunction and myocardial damage are present during 
acute HIV infection, and improve with viral suppression.(38) NT-
proBNP was used as a surrogate for ventricular functioning 
while troponin T represented myocardial injury. NT-proBNP 
and troponin T showed significant correlation with the plasma 
viral load. The authors speculate that the inflammatory surge, 
high HIV viral load, and immunosuppression experienced during 
acute HIV infection, may be the cornerstone of progressive 
myocardial disease. This represents the earliest possible time 
point that HIV may affect the myocardium. Unfortunately, no 
imaging was performed in this study, and it would have been 
 
fIgURe 3:  The perfect storm: Creating a cardiomyopathy in HIV. 
multiple underlying risk factors work synergistically to initiate and perpetuate chronic myocardial inflammation. Chronic myocardial inflammation 
causes cumulative myocardial damage, leading to myocardial fibrosis and remodelling. patients in various stages of HIV and degrees of myocardial 
abnormality are receiving anti-retroviral treatment (ArT). This “Black Box”-environment remain largely unexplored and it is unclear how 
myocardial pathology will evolve on ArT. The study of patients before and on ArT may provide clues to shed light on the complex patho-

































enlightening to correlate these findings with observed cardiac 
functioning and CMR’s virtual histology.
A unifying hypothesis would be that we are observing snap-
shots of the same disease process over time on a continuum 
towards dilated, poorly functional ventricles. Myocardial inflam-
mation appears to be a common end-point for various driving 
processes. Prospective research is lacking to provide additional 
evidence for this hypothesis. 
Another shortcoming of currently available literature is the 
underrepresentation of the developing world in research. 
Cohorts are dominated by older, Caucasian males that do not 
live in the same environment as the majority of PLWH; namely 
younger, African females in low- to middle-income countries.(5) 
The spectrum of cardiovascular disease is reliant on the specific 
population group and their environment.(6) Differences that 
might plausibly change observed cardiovascular disease include 
host genetics, prevalent co-infections and their modulatory 
effect on the immune system, as well as delayed presentation 
and treatment in resource limited settings. These factors may 
further limit our understanding of the already complex pro-
cesses at play.
Research evaluating asymptomatic, ART naive persons in the 
developing world will provide a novel perspective on HIVAC. 
It is possible that the underlying burden of cardiomyopathy 
differs significantly from data predominantly generated in the 
developed world. Furthermore, future study in this field should 
aim to better represent non-Caucasian people and females. 
The identification of abnormal tissue characteristics in asympto-
matic, ART naive PLWH will allow for prospective, serial 
evaluation with CMR after initiation on ART. 
CONClUsION
HIVAC is an incompletely understood disease-group with a 
poor prognosis once established ventricular dysfunction is pre-
sent. The pathophysiology is complex with multiple processes 
likely working synergistically to set in motion and maintain a 
state of chronic myocardial inflammation. In turn, chronic 
inflammation drives cardiac fibrosis and remodelling.
An overlap of ventricular inflammation, oedema and fibrosis is 
demonstrable in symptomatic and asymptomatic persons with 
HIVAC. This phenomenon, together with evidence of a high 
burden of early myocardial involvement in PLWH, creates the 
impression that we are observing the same pathology at 
different time points on a continuum from asymptomatic 
myocardial inflammation towards end stage dilated cardio-
myopathy. 
Serial evaluation using CMR’s virtual histology approach is an 
exciting tool to investigate HIVAC. This prospective approach 
will enable us to peek into the previously inaccessible “Black 
Box” and observe real time pathology. Information on the 
evolution of myocardial abnormalities on ART is needed. Cur-
rent CMR evidence suggests the concerning notion that ART 
alone does not fully address cardiovascular inflammation asso-
ciated with HIV infection. As the authors have explored, most, 
if not all, PLWH appear to have some degree of underlying 
myocardial abnormality. It is unclear what subset of these 
patients will continue to progress towards end-stage cardio-
myopathy. The ability to accurately predict this will only be 
made possible by improving our understanding of the disease 
process.
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